BLUE
Iicr-ctsu.bsky.social

At #ESMO24 this week, Prof Christina B Yap presented 'How much do real world patients really differ from clinical trials?' in the session on How Real World Data (RWD) are transforming oncology.

0
JXjordixiol.bsky.social

#ESMO24 A summary of presentations that caught my eye: - STX-478 inhibitor in PIK3CA mutant tumors - BMS-986365 AR degrader/antagonist in mCRPC - BNT327 PD-L1/VEGF in EGFR-mutated NSCLC - NVL-655 inhibitor in ALK-mutated NSCLC - Ponsegromab anti-GDF15 for cancer patients with cachexia

0

ESMO 2024 Le PIONeeR Project présente pour la première fois les résultats de son étude clinique de phase Ib/IIa. fr.ap-hm.fr/actu/esmo-20...#ESMO24#PIONeeRProject#Oncologie#Immunothérapie#RechercheMédicale#NSCLC#CancerDuPoumon#InnovationSanté#Phase1b2a#EssaiClinique#RHU#Marseille

1
AKthealexknapp.bsky.social

Retroactive study presented at a conference over the weekend suggests that mRNA vaccines might boost the efficacy of cancer immunotherapy treatments. More work would need to be done to show if this is a real effect but it's interesting. endpts.com/esmo24-in-su...

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy
In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

The mRNA-based Covid vaccines used by hundreds of millions of people may provide an unexpected benefit to some cancer patients, significantly improving survival when given within a few months of immun...

0
JXjordixiol.bsky.social

Chemotherapy still preferred over Pluvicto in 2L mCRPC. Pluvicto is the SOC after chemo $NVS #ESMO24

0
JXjordixiol.bsky.social

Some competition for $RVMD at #ESMO24. Astellas' KRAS G12D degrader shows 33% ORR at the highest dose (n=12), with 42% in PDAC (n=7). Still low n, but as a reference $RVMD had a 27% ORR in Ras-mutant PDAC

0
JXjordixiol.bsky.social

It would be nice to build a biotech community on this site. In three weeks I’ll be attending #ESMO24 and I’ll post some content here. Let’s see if we can bring some coverage of the conference here

0